New treatments for multiple sclerosis.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D004041:Dietary Fats / Q000627:therapeutic use; D005983:Glutens / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D008041:Linoleic Acids / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000178:diet therapy / Q000276:immunology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use; D014165:Transfer Factor / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D004041:Dietary Fats; D007166:Immunosuppressive Agents; D008041:Linoleic Acids; D004676:Myelin Basic Protein; D014165:Transfer Factor; D007978:Levamisole; D005983:Glutens; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone; D001379:Azathioprine; D008775:Methylprednisolone